Fares Al‐Ejeh

3.8k total citations
53 papers, 1.8k citations indexed

About

Fares Al‐Ejeh is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Fares Al‐Ejeh has authored 53 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 27 papers in Oncology and 12 papers in Cancer Research. Recurrent topics in Fares Al‐Ejeh's work include Cancer Cells and Metastasis (7 papers), Cancer-related Molecular Pathways (7 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Fares Al‐Ejeh is often cited by papers focused on Cancer Cells and Metastasis (7 papers), Cancer-related Molecular Pathways (7 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Fares Al‐Ejeh collaborates with scholars based in Australia, Qatar and United Kingdom. Fares Al‐Ejeh's co-authors include Michael P. Brown, Kum Kum Khanna, Sunil R. Lakhani, Jocelyn M. Darby, Adrian P. Wiegmans, Georgia Chenevix‐Trench, Mariska Miranda, David F. Callen, Paul M. Neilsen and Peter T. Simpson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Advanced Materials and Journal of Biological Chemistry.

In The Last Decade

Fares Al‐Ejeh

51 papers receiving 1.8k citations

Peers

Countries citing papers authored by Fares Al‐Ejeh

Since Specialization

Citations

This map shows the geographic impact of Fares Al‐Ejeh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fares Al‐Ejeh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fares Al‐Ejeh more than expected).

Fields of papers citing papers by Fares Al‐Ejeh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fares Al‐Ejeh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fares Al‐Ejeh. The network helps show where Fares Al‐Ejeh may publish in the future.

Co-authorship network of co-authors of Fares Al‐Ejeh

This figure shows the co-authorship network connecting the top 25 collaborators of Fares Al‐Ejeh. A scholar is included among the top collaborators of Fares Al‐Ejeh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fares Al‐Ejeh. Fares Al‐Ejeh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cancer Incidence and Mortality Estimates in Arab Countries in 2018: A GLOBOCAN Data Analysis 2023 ·Cancer Epidemiology Biomarkers & Prevention ·(unknown), Fares Al‐Ejeh	10
2	G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma 2021 ·Clinical Cancer Research ·Greg Kelly, Fares Al‐Ejeh, Robert McCuaig, Francesco Casciello, (unknown), Blake Ferguson, Antonia L. Pritchard, Sayed Ali, Inês Pires da Silva, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Sudha Rao, Nicholas K. Hayward, Frank Gannon, Jason S. Lee	29
3	Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient 2018 ·Breast Cancer Research and Treatment ·(unknown), (unknown), Jodi M. Saunus, Chanel E. Smart, Sarah Song, Rebecca L. Johnston, Sibylle Cocciardi, Esdy Rozali, Cameron N. Johnstone, (unknown), Stephen H. Kazakoff, (unknown), Kum Kum Khanna, Sunil R. Lakhani, Georgia Chenevix‐Trench, Peter T. Simpson, Kátia Nones, Nicola Waddell, Fares Al‐Ejeh	5
4	G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis 2017 ·Proceedings of the National Academy of Sciences ·Francesco Casciello, Fares Al‐Ejeh, Greg Kelly, Donal J. Brennan, Shin Foong Ngiow, Arabella Young, Thomas Stoll, Karolina Windloch, Michelle M. Hill, Mark J. Smyth, Frank Gannon, Jason S. Lee	104
5	Quinazolinone derivatives as inhibitors of homologous recombinase RAD51 2017 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), (unknown), Jonathan M. Harris, Kum Kum Khanna, Fares Al‐Ejeh, David P. Fairlie, Adrian P. Wiegmans, Ligong Liu	17
6	MITF and BRN2 contribute to metastatic growth after dissemination of melanoma 2017 ·Scientific Reports ·Jacinta L. Simmons, Carly J. Pierce, Fares Al‐Ejeh, Glen M. Boyle	40
7	Long-range regulators of the lncRNAHOTAIRenhance its prognostic potential in breast cancer 2016 ·Human Molecular Genetics ·Michael J. G. Milevskiy, Fares Al‐Ejeh, Jodi M. Saunus, Korinne Northwood, Peter J. Bailey, Joshua A. Betts, Amy E. McCart Reed, Kenneth P. Nephew, Andrew Stone, Julia M.W. Gee, Dennis H. Dowhan, Eloïse Dray, Annette M. Shewan, Juliet D. French, Stacey L. Edwards, Susan J. Clark, Sunil R. Lakhani, Melissa A. Brown	58
8	EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia 2016 ·Leukemia ·Sara Charmsaz, Fares Al‐Ejeh, Trina Yeadon, (unknown), Fiona Smith, Brett W. Stringer, Andrew S. Moore, (unknown), L Cooper, (unknown), Geoffrey Yarranton, John Woronicz, Andrew M. Scott, Martin Lackmann, Andy Boyd	28
9	Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib 2015 ·PLoS ONE ·(unknown), Erik Tilch, (unknown), Michael C. Quinn, Adrian P. Wiegmans, Wei Shi, Sibylle Cocciardi, Amy E. McCart Reed, Jodi M. Saunus, Peter T. Simpson, Sean M. Grimmond, Sunil R. Lakhani, Kum Kum Khanna, Nicola Waddell, Fares Al‐Ejeh, Georgia Chenevix‐Trench	24
10	EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia 2015 ·PLoS ONE ·Sara Charmsaz, (unknown), Fiona Smith, Claudia Bruedigam, Andrew S. Moore, Fares Al‐Ejeh, Steven Lane, Andy Boyd	19
11	Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma 2014 ·Clinical Cancer Research ·Fares Al‐Ejeh, Marina Pajic, Wei Shi, Murugan Kalimutho, Mariska Miranda, Adnan Nagrial, Angela Chou, Andrew V. Biankin, Sean M. Grimmond, (unknown), Michael P. Brown, Kum Kum Khanna	31
12	Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer 2014 ·Oncogenesis ·Fares Al‐Ejeh, Peter T. Simpson, (unknown), Kerenaftali Klein, Murugan Kalimutho, Wei Shi, Mariska Miranda, Jamie R. Kutasovic, Akshara Singareeka Raghavendra, Jason Madore, Lynne Reid, Lutz Krause, Georgia Chenevix‐Trench, Sunil R. Lakhani, Kum Kum Khanna	80
13	Eph family co-expression patterns define unique clusters predictive of cancer phenotype 2014 ·Growth Factors ·Fares Al‐Ejeh, Carolin Offenhäuser, Yi Chieh Lim, Brett W. Stringer, Bryan W. Day, Andy Boyd	7
14	Breast cancer stem cells: treatment resistance and therapeutic opportunities 2011 ·Carcinogenesis ·Fares Al‐Ejeh, Chanel E. Smart, Brian J. Morrison, Georgia Chenevix‐Trench, J. Alejandro López, Sunil R. Lakhani, Michael P. Brown, Kum Kum Khanna	103
15	Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11 2011 ·Oncogene ·Jacqueline E. Noll, Jessie Jeffery, Fares Al‐Ejeh, Raman Kumar, Kum Kum Khanna, David F. Callen, Paul M. Neilsen	59
16	Nutlin-3a Is a Potential Therapeutic for Ewing Sarcoma 2010 ·Clinical Cancer Research ·Kathleen I. Pishas, Fares Al‐Ejeh, Irene Zinonos, Raman Kumar, Andreas Evdokiou, Michael P. Brown, David F. Callen, Paul M. Neilsen	59
17	Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes 2010 ·Oncogene ·Fares Al‐Ejeh, Rajesh Kumar, Adrian P. Wiegmans, Sunil R. Lakhani, Michael P. Brown, Kum Kum Khanna	115
18	Multifunctional core–shell magnetic cisplatin nanocarriers 2009 ·Chemical Communications ·Benjamin Thierry, Fares Al‐Ejeh, Aparajita Khatri, Zhe Yuan, Pamela J. Russell, (unknown), Michael P. Brown, Peter Majewski	30
19	APOMAB®, a La-Specific Monoclonal Antibody, Detects the Apoptotic Tumor Response to Life-Prolonging and DNA-Damaging Chemotherapy 2009 ·PLoS ONE ·Fares Al‐Ejeh, Jocelyn M. Darby, Chris Tsopelas, Douglas R. Smyth, Jim Manavis, Michael P. Brown	32
20	Chemotherapy Synergizes with Radioimmunotherapy Targeting La Autoantigen in Tumors 2009 ·PLoS ONE ·Fares Al‐Ejeh, Jocelyn M. Darby, Michael P. Brown	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact